[vc_row][vc_column][vc_column_text] InhibOx Receives Investment to Fight Drug-Resistant Bacteria The National Foundation for Cancer Research is delighted that computer-aided drug-resistance research is now getting increased funding across the pond! NFCR lauds the selection of InhibOx Ltd. as the company to receive a nearly £1 million grant from Innovate...
Molecular imaging combines conventional anatomic imaging with genomic testing and enables doctors to literally see cancer at its molecular or genetic level....
Dr. Web Cavenee and Dr. Paul B. Fisher discover a new pharmacological agent to treat glioblastoma multiforme (GBM), the deadliest brain cancer....
Researchers from UNC, Chapel Hill found a subtype of bladder cancer has the same molecular signatures as a subset of breast cancer....
A method called MishCTC is being developed that will detect a molecular biomarker that is inside tumor cells but can’t be detected in normal blood cells....
The U.S. FDA approved the first and only drug to treat people with advanced non-small cell lung cancer (NSCLC) whose tumors express the ROS1+ mutation....
Oscillating expression of a key cancer gene may impact treatment approaches for patients NFCR-supported scientist Dr. Daniel Haber and his team at the Massachusetts General Hospital Cancer Center have identified a dynamic gene expression in metastatic breast cancer that may contribute to disease progression and resistance to...
Can you imagine that a Guinness world record could be related to genetic sequencing and disease diagnosis? A world record for fastest genetic diagnosis was recently set by Dr. Stephen Kingsmore, president and CEO of Rady Children's Institute for Genomic Medicine. Dr. Kingsmore is able...
[vc_row][vc_column width="1/2"][vc_column_text css=""]Clinical Trial and Translational Medicine. Our CEO, the son of the Founder of NFCR, likes to talk about history. Franklin C. Salisbury, Jr. notes the coincidence, perhaps, that the Salisbury name has long been associated with unheralded basic research that leads to major...
New Treatments Could Shrink Breast Cancer in Just 11 Days For patients with HER2-positive breast cancer, a new combination therapy with two drugs could shrink or even eliminate their tumors in just 11 days. About 10% of breast cancers are HER2-positive, which is a subtype of breast...
Search NFCR
Popular searches